Search results
Results From The WOW.Com Content Network
Bausch & Lomb (since 2010 stylized as Bausch + Lomb [2]) is an American-Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, [3] lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. [4] [5] The company was founded in Rochester ...
Bausch Health. Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International, Inc.) is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders ...
The national drug code (NDC) is a unique product identifier used in the United States for drugs intended for human use. The Drug Listing Act of 1972 [1] [2] requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, compounded, or processed by it ...
(Reuters) - The U.S. Food and Drug Administration (FDA) on Wednesday warned consumers not to use unapproved eye drops that closely resemble Bausch + Lomb's Lumify product for redness relief.
Bausch has said the litigation could affect its plans to spin off its eye-care business Bausch + Lomb. Analysts at Jefferies said on Thursday that the decision removes a "key barrier" for the spinoff.
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares ...
Miracle-Ear, Inc. is a hearing aid and hearing care company consisting of a network of franchised and corporately owned retail locations. The company is a subsidiary of Amplifon, the worldwide leader in hearing care and hearing aid retail based in Milan, Italy. [1] Miracle-Ear's U.S. headquarters are located in Minneapolis, Minnesota. [2]
Reuters reports that Bausch Health Companies Inc (NYSE: BHC) will pay $300 million to settle an antitrust lawsuit related to illegally maintaining a monopoly on diabetes drug Glumetza. The FDA ...